Affect of Daratumumab on Laboratory Blood Test Results

Share this content:
Daratumumab can cause erratic false positives in a blood antibody screen obtained before transfusion.
Daratumumab can cause erratic false positives in a blood antibody screen obtained before transfusion.

Daratumumab can cause erratic false positives in the blood antibody screen and crossmatch obtained prior to a transfusion. Does this phenomenon occur with other monoclonal antibodies? —Name withheld on request

 

The issues with blood crossmatch are due to daratumumab's effects on CD-38, which is also expressed on red blood cells; therefore, the phenomenon is not expected to occur with other monoclonal antibodies currently on the market that do not bind to CD-38 receptors on red blood cells. 

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs